13383-07-8

Usage

Chiral compound

Yes

Type of medication

Beta blocker

Uses

Treatment of heart rhythm disorders such as ventricular arrhythmias and atrial fibrillation

Mechanism of action

Slows down the heart rate and regulates irregular heart rhythms

Route of administration

Oral

Potential side effects

Dizziness, fatigue, and low blood pressure

Precautions

Use under the supervision of a healthcare professional.

Upstream product

• 100-39-0 benzyl bromide 
• 76-83-5 trityl chloride 
• 17618-04-1 2,5-di-O-benzyl-D-mannitol 
• 322468-17-7 (R)-2-O-benzyl-3-O-tritylglycerol aldehyde 
• 90126-86-6 2,5-di-O-benzyl-1,6-di-O-trityl-D-mannitol 
• 16814-88-3 methyl (2R)-2-methoxy-3-(triphenylmethoxy)propanoate 
• 114978-02-8 2,5-di-O-benzyl-1,3(R):4,6(R)-di-O-benzylidene-D-mannitol 

Downstream Products

• 10334-31-3 (S)-2-Benzyloxycarbonylamino-propionic acid (R)-2-benzyloxy-3-trityloxy-propyl ester 
• 114935-28-3 (R)-2-benzyloxy-3-tert-butyldiphenylsilanyloxy-propan-1-ol 
• 322468-27-9 ((S)-2-O-benzyl-glyceryl)-2-bromoethyl-methylphosphate 
• 322468-25-7 ((R)-2-O-benzyl-glyceryl)-2-bromoethyl-methylphosphate 
• 322468-34-8 (3-O-[2-propyl pentanoyl]-(R)-2-O-benzylglyceryl)-2-bromoethyl-methyl phosphate 
• 322468-29-1 (3-O-[2-(4-isobutlyphenyl propanoyl)]-(R)-2-O-benzylglyceryl)-2-bromoethyl-methyl phosphate 
• 322468-31-5 (3-O-[2-(4-isobutlyphenyl propanoyl)]-(S)-2-O-benzylglyceryl)-2-bromoethyl-methyl phosphate 
• 322468-21-3 ((R)-2-O-benzyl-3-O-tritylglyceryl)-2-bromoethyl-methyl phosphate 
• 18867-58-8 (S)-2-Benzyloxycarbonylamino-propionic acid (R)-2-benzyloxy-3-iodo-propyl ester 
• 16990-57-1 (R)-2-Benzyloxy-3-iod-propan-1-ol 
• 10334-33-5 S-α-(N-Carbobenzoxy-L-alanyl)-β-O-benzyl-γ-glyceroliodid 
• 10334-32-4 R-α-(N-Carbobenzoxy-L-alanyl)-β-O-benzyl-glycerol 
• 30563-15-6 1-O-trityl-3-O-palmitoyl-sn-glycerol 
• 98244-36-1 (S)-2-benzyloxy-1-hexadecyloxy-3-trityloxy-propane 

Relevant academic research and scientific papers

Drug-phospholipid conjugates as potential prodrugs: Synthesis, characterization, and degradation by pancreatic phospholipase A2

The aim of the present study was the synthesis of phospholipids containing a drug molecule instead of a fatty acid. Valproic acid and ibuprofen served as model compounds. The target molecules were synthesized either starting from sn-glycero-3-phosphocholi

Asymmetric induction during carbonylation of an optically active organopalladium. A novel and versatile route to enantiomeric glycerides.

In the course of carbonylation of optically active [η5-C5H5Feη5- CH5H3CH2NMe2PdCl]2 (1) in prochiral diols, the asymmetric induction of a newly developed chiral centre by a chiral plane has been performed. For 2-O-benzyl- glycerol, the extent of asymmetric induction, that means diastereoselectivity, was found to be about 36%. The protection of a free hydroxyl followed by hydrolysis of a ferrocenoyl derivative resulted in enantiomeric 2-O-benzyl-3-O-trityl-sn-glycerol (4) which can serve as a key intermediate in the synthesis of optically active mono-, di- and tri-substituted glycerides. This methodology has been illustrated by the detailed description of the preparation of 1-palmitoyl-sn-glycerol.